| Type | Subsidiary |
| Parent Company | Biogen |
| HQ | Newton, MA, US |
| Founded | 2008 |
| Website | karyopharm.com |
| Cybersecurity rating | BMore |
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, MA, US
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Karyopharm Therapeutics
Garen Bohlin
Director
Richard Paulson
President and Chief Executive Officer, Director
Brian Austad
Senior Vice President, Pharmaceutical Sciences
Mikael Dolsten
Director
Sharon Shacham
Co-Founder, Chief Scientific Officer
Michael G. Kauffman
Co-Founder, Senior Clinical Advisor
Karyopharm Therapeutics Office Locations
Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo
Newton, MA, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg
Tel Aviv-Yafo, IL
Yigal Alon St 94
Karyopharm Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2008 |
Total Funding | $248.7 m |
Investors | New Leaf Venture Partners, Delphi Ventures, Foresite Capital |
Karyopharm Therapeutics is a subsidiary of Biogen
Karyopharm Therapeutics Revenue
Karyopharm Therapeutics's revenue was reported to be $108.09 m in FY, 2020
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 171.0k | 21.0k | 21.0k | 150.0k | 75.0k | 59.0k | 48.0k | 68.0k | 19.9m | 239.0k | 155.0k | 9.5m | 13.1m | 18.1m | 33.5m | 21.3m | 23.3m | ||||||
Cost of goods sold | 1.0m | ||||||||||||||||||||||
Gross profit | 12.1m | ||||||||||||||||||||||
Gross profit Margin, % | 92% |
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 52.9m | 144.9m | 132.3m | 227.1m | 51.5m | 24.2m | 43.5m | 42.2m | 37.7m | 43.9m | 25.6m | 55.4m | 54.5m | 37.5m | 119.0m | 101.6m | 83.5m | 75.5m | 168.0m | 202.2m | 103.1m | 82.3m | |
Accounts Receivable | 7.9m | 9.3m | 9.6m | ||||||||||||||||||||
Prepaid Expenses | 658.0k | 2.7m | 3.0m | 4.2m | 2.9m | 4.1m | 3.1m | 1.7m | 1.5m | 3.4m | 2.1m | 2.1m | 2.1m | 2.4m | 3.4m | 4.8m | 7.0m | 5.7m | 5.3m | 7.6m | 8.0m | 8.2m | |
Inventories | 100.0k | 970.0k | 1.7m | 2.0m |
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|---|---|---|---|---|
Net Income | (33.9m) | (75.8m) | (118.2m) | (109.6m) | (129.0m) | (178.4m) | (199.6m) | (196.3m) |
Depreciation and Amortization | 144.0k | 323.0k | 634.0k | 717.0k | 713.0k | 735.0k | 974.0k | 972.0k |
Inventories | (346.0k) | (2.6m) | ||||||
Accounts Payable | 664.0k | 4.5m | (2.4m) | 945.0k | 909.0k | (1.4m) | (3.3m) | 3.5m |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (21.8m) | (13.7m) | (30.1m) | (49.8m) | (26.1m) | (58.8m) | (89.1m) | (27.1m) | (57.2m) | (82.6m) | (29.9m) | (59.3m) | (89.9m) | (38.5m) | (72.1m) | (120.2m) | (66.2m) | (109.6m) | (150.9m) | (52.9m) | (99.4m) | (152.9m) | (57.4m) |
Depreciation and Amortization | 106.0k | 43.0k | 85.0k | 191.0k | 136.0k | 292.0k | 457.0k | 179.0k | 358.0k | 537.0k | 183.0k | 363.0k | 539.0k | 169.0k | 353.0k | 541.0k | 245.0k | 487.0k | 730.0k | 242.0k | 480.0k | 715.0k | 235.0k |
Inventories | (100.0k) | (624.0k) | (1.3m) | (1.7m) | (552.0k) | ||||||||||||||||||
Accounts Payable | 673.0k | 1.5m | 1.7m | 362.0k | 268.0k | (1.8m) | (2.1m) | 294.0k | 233.0k | (1.7m) | (522.0k) | (1.5m) | (2.9m) | (773.0k) | (1.9m) | (3.4m) | (2.0m) | (3.2m) | (1.2m) | 711.0k | 903.0k | 1.4m | (1.4m) |
- Source: SEC Filings
| USD | Q3, 2013 |
|---|---|
Financial Leverage | -1.2 x |
Karyopharm Therapeutics Cybersecurity Score
Karyopharm Therapeutics Online and Social Media Presence
Karyopharm Therapeutics's Trends
Karyopharm Therapeutics Company Culture
Overall Culture
A
79/100
CEO Rating
A+
87/100
Compensation
A+
91/100
Diversity
B
78/100
Karyopharm Therapeutics News and Updates
June 09, 2021
Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS
--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 8, 2021 /PRNewswire/ -- Antengene's Partner, Karyopharm...
December 21, 2020
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
SHANGHAI and HONG KONG, Dec. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc....
September 20, 2019
KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
New York, NY - (NewMediaWire) - September 20, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a fede…
September 19, 2019
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities...
August 02, 2019
ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - KPTI
NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the...
July 27, 2019
KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against...
Karyopharm Therapeutics Blogs
June 24, 2021
Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million
− Investment Expected to Extend Karyopharm's Cash Runway into the Middle of 2023 -
June 08, 2021
Karyopharm Announces Key Changes to Its Commercial Leadership Team
− Sohanya Cheng, Formerly of Amgen and Arrowhead Pharmaceuticals, Appointed as Head of Sales and Commercial Operations -
June 03, 2021
Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets
-- Three New Strength Tablets Approved by the FDA: 40 mg, 50 mg and 60 mg --
June 02, 2021
Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
-- NEXPOVIO is the First and Only Nuclear Export Inhibitor Authorized in the UK --
Karyopharm Therapeutics Frequently Asked Questions
When was Karyopharm Therapeutics founded?
Karyopharm Therapeutics was founded in 2008.
Who are Karyopharm Therapeutics key executives?
Karyopharm Therapeutics's key executives are Garen Bohlin, Richard Paulson and Brian Austad.
How many employees does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 487 employees.
What is Karyopharm Therapeutics revenue?
Latest Karyopharm Therapeutics annual revenue is $108.1 m.
What is Karyopharm Therapeutics revenue per employee?
Latest Karyopharm Therapeutics revenue per employee is $221.9 k.
Who are Karyopharm Therapeutics competitors?
Competitors of Karyopharm Therapeutics include Halozyme Therapeutics, Jiangsu Hansoh Pharmaceutical Group and Ethypharm.
Where is Karyopharm Therapeutics headquarters?
Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.
Where are Karyopharm Therapeutics offices?
Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo.
How many offices does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies